VaxGen, Inc. Provides Update Regarding Biodefense Presentations

BRISBANE, Calif., April 24 /PRNewswire-FirstCall/ -- VaxGen, Inc. today announced that it has postponed a presentation by its Senior Vice President of Research and Development at a pre-conference symposium scheduled for today but that the company' President and Chief Executive will participate, as previously scheduled, in a biodefense panel during the main part of the conference tomorrow.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO )

VaxGen chose to postpone a presentation by Kathrin Jansen, Ph.D., titled "Development of a Recombinant Anthrax (rPA) Vaccine" scheduled for today at the 4th Annual Bio-Chem Defense and Pandemic Vaccines and Therapeutics Meeting in Washington, D.C., pending completion of the company's review of its scientific communication protocols to ensure that they are consistent with Food and Drug Administration regulations. The decision is unrelated to the quality of the data in Dr. Jansen's presentation or any aspect of the company's recombinant anthrax vaccine program, and VaxGen looks forward to presenting these and other data at scientific conferences in the near future.

VaxGen President and CEO Lance K. Gordon, Ph.D., is scheduled to participate Tuesday, April 25, 2006 on a conference panel titled "Building a Bio-Chem Defense and Pandemic Vaccine and Therapeutic Industry." The panel will discuss the conditions necessary to garner industry involvement in developing and providing defenses against the threat of biologic and chemical attacks.

Additional information about the conference can be found at http://www.infocastinc.com/biovac06.html

Note: This press release contains "forward-looking statements" within the meaning of the federal securities laws. These forward-looking statements include without limitation, statements regarding the timing and ability of the company's ability to present scientific data at forthcoming scientific conferences. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated. Reference should be made to Item 8.01 of the company's Current Report on Form 8-K filed by VaxGen on February 16, 2006 under the heading "Risk Factors" for a more detailed description of such risks. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. VaxGen undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.

CONTACT: Paul Laland, Vice President, Public Affairs, +1-650-624-2345, orFor Investors and Financial Analysts: Lance Ignon, Vice President,Corporate Affairs, +1-650-624-1016, both of VaxGen, Inc.

Web site: http://www.vaxgen.com/